FDA is taking an initial step to advance treatment options for men’s health by encouraging sponsors of approved testosterone replacement therapy products to contact FDA for information if they are interested in pursuing a potential new indication for low libido in men with idiopathic hypogonadism.
FDA News Releases published a clinical update in Research Highlights on 16 Apr 2026. The item focuses on FDA Takes Step Forward on Testosterone Therapy for Men. Open the detail page to review the full original feed content.